Compare iShares Global Clean Energy ETF (ICLN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs TG Therapeutics Inc — how do they compare? iShares Global Clean Energy ETF trades at $18.42, while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: TG Therapeutics Inc is trading nearer its 52-week high, iShares Global Clean Energy ETF nearer its low. Which is the better fit depends on your goals.
| ICLN | TGTX | |
|---|---|---|
52-Week High | $23.75 | $59.06 |
52-Week Low | $13.66 | $26.94 |
Market Cap | — | $7.64B |
Sector | — | Health |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN, the iShares Global Clean Energy ETF, trades at $18.41, up 1.83% today, but technical indicators signal a bearish trend with moving averages and overall momentum pointing lower. The fund provides exposure to 105 global renewable energy companies, though key valuation and profitability ratios are not publicly disclosed for the ETF itself. Recent news highlights strong 2026 performance with over 25% gains, driven by global energy security concerns and data center power demand, though it faces competition from traditional energy ETFs offering lower fees and higher yields.
The outlook for ICLN is mixed; clean energy tailwinds from policy support and electrification trends offer growth potential, but risks include regulatory hurdles, fee competitiveness, and volatility. Analyst sentiment is cautious due to fee comparisons and policy dependence, with institutional interest balanced against outperformance of alternatives like uranium ETFs. Investment suitability hinges on appetite for clean energy sector volatility versus stable income.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
